Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
60.69B
Market cap60.69B
Price-Earnings ratio
14.11
Price-Earnings ratio14.11
Dividend yield
0.47%
Dividend yield0.47%
Average volume
968.98K
Average volume968.98K
High today
$575.43
High today$575.43
Low today
$558.54
Low today$558.54
Open price
$558.54
Open price$558.54
Volume
995.18K
Volume995.18K
52 Week high
$1,165.85
52 Week high$1,165.85
52 Week low
$476.49
52 Week low$476.49

REGN News

Simply Wall St 2d
Does Regeneron Offer Value After Shares Slide 21.7% Year to Date in 2025?

If you have ever wondered whether now is the right time to buy, hold, or reconsider Regeneron Pharmaceuticals, you are definitely not alone. The company has bee...

Does Regeneron Offer Value After Shares Slide 21.7% Year to Date in 2025?
Benzinga 6d
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy

Regeneron Pharmaceuticals, Inc. REGN on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo...

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy
TipRanks 7d
Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron, with a price target of $640.00. Elevate Your Investing Str...

Analyst ratings

79%

of 28 ratings
Buy
78.6%
Hold
17.9%
Sell
3.6%

More REGN News

TipRanks 7d
Regeneron announces follow-up results on Phase 3 EMPOWER-Lung 3 trial

Regeneron (REGN) Pharmaceuticals announced five-year follow-up results on overall survival from the Phase 3 EMPOWER-Lung 3 trial, which evaluated Libtayo plus p...

TipRanks 7d
Sandoz reaches agreement with Regeneron over patent litigation

Sandoz (SDZNY) announced that it has reached an agreement with Regeneron Pharmaceuticals (REGN), to resolve all patent disputes between the two companies relati...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.